CY1119774T1 - Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2 - Google Patents

Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2

Info

Publication number
CY1119774T1
CY1119774T1 CY20161101107T CY161101107T CY1119774T1 CY 1119774 T1 CY1119774 T1 CY 1119774T1 CY 20161101107 T CY20161101107 T CY 20161101107T CY 161101107 T CY161101107 T CY 161101107T CY 1119774 T1 CY1119774 T1 CY 1119774T1
Authority
CY
Cyprus
Prior art keywords
fgfr1
determinative
extractive
protective
protection
Prior art date
Application number
CY20161101107T
Other languages
English (en)
Inventor
Thomas Harding
Michael W. Kavanaugh
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of CY1119774T1 publication Critical patent/CY1119774T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση πολυπεπτιδίων του εξωκυτταρικού πεδίου (ECD) του Υποδοχέα του Αυξητικού Παράγοντα Ινοβλαστών I (FGFR1) για την αγωγή των καρκίνων που χαρακτηρίζονται από εξαρτώμενες από πρόσδεμα ενεργοποιητικές μεταλλάξεις στον Υποδοχέα Αυξητικού Παράγοντα Ινοβλαστών 2 (FGFR2). Για παράδειγμα, η παρούσα εφεύρεση αναφέρεται στην αγωγή καρκίνων του ενδομητρίου και άλλων καρκίνων όπου τα κύτταρα του όγκου εκφράζουν μεταλλάγματα FGFR2 στην περιοχή αρθρώσεως Igll-lglll ή στο πεδίο Iglll της πρωτεΐνης, όπως στις θέσεις αμινοξέων 252 και/ή 253.
CY20161101107T 2009-11-13 2016-10-27 Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2 CY1119774T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26129109P 2009-11-13 2009-11-13
PCT/US2010/056627 WO2011060333A1 (en) 2009-11-13 2010-11-12 Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

Publications (1)

Publication Number Publication Date
CY1119774T1 true CY1119774T1 (el) 2018-06-27

Family

ID=43992083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101107T CY1119774T1 (el) 2009-11-13 2016-10-27 Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2

Country Status (11)

Country Link
US (2) US8614183B2 (el)
EP (1) EP2498799B1 (el)
AU (1) AU2010319327B2 (el)
CA (1) CA2780457A1 (el)
CY (1) CY1119774T1 (el)
DK (1) DK2498799T3 (el)
ES (1) ES2600631T3 (el)
LT (1) LT2498799T (el)
PL (1) PL2498799T3 (el)
PT (1) PT2498799T (el)
WO (1) WO2011060333A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
AU2015249133C1 (en) * 2010-11-15 2017-08-17 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2011329127B2 (en) * 2010-11-15 2015-09-03 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
SG11201900074WA (en) 2016-07-07 2019-02-27 Therachon Sas Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486462A (en) 1984-11-23 1996-01-23 The Regents Of The University Of California Differentiative expression modules
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
GB9001466D0 (en) 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5750371A (en) 1990-04-27 1998-05-12 Takeda Chemical Industries Ltd Water-soluble mutein of FGF receptor, DNA and production thereof
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
DE69133281T2 (de) 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
RS20120253A1 (en) 2001-05-24 2013-02-28 Zymogenetics Inc. TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS
US20050187150A1 (en) 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
AU2003249055B2 (en) 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
JP2008506366A (ja) 2004-05-14 2008-03-06 レセプター バイオロジックス インコーポレイテッド 細胞表面受容体アイソフォームならびにその同定および使用方法
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
AU2006207999A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2007059574A1 (en) 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US7678373B2 (en) 2006-02-10 2010-03-16 Genentech, Inc. Anti-FGF19 antibodies and methods using same
WO2007134210A2 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
CA2680046A1 (en) 2007-03-23 2008-10-02 The Translational Genomics Research Institute Methods of diagnosing, classifying and treating endometrial cancer and precancer
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2012125812A1 (en) 2011-03-17 2012-09-20 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression

Also Published As

Publication number Publication date
US9169313B2 (en) 2015-10-27
EP2498799A4 (en) 2013-12-18
PL2498799T3 (pl) 2017-03-31
WO2011060333A1 (en) 2011-05-19
EP2498799B1 (en) 2016-08-17
ES2600631T3 (es) 2017-02-10
EP2498799A1 (en) 2012-09-19
AU2010319327B2 (en) 2015-08-13
PT2498799T (pt) 2016-11-04
AU2010319327A1 (en) 2012-05-31
LT2498799T (lt) 2016-11-10
CA2780457A1 (en) 2011-05-19
US8614183B2 (en) 2013-12-24
DK2498799T3 (en) 2016-12-05
US20140227263A1 (en) 2014-08-14
US20120251538A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
CY1119774T1 (el) Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2
AU2021201484B2 (en) Chimeric antigen receptors and methods of use
CY1123192T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldν6)
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
NZ754051A (en) Novel antibodies and uses thereof
CY1122651T1 (el) Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
CY1118608T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
EA201491644A1 (ru) Фармацевтические композиции
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
MY196882A (en) Recombinant binding proteins and their use
TW200732347A (en) VEGF analogs and methods of use
MX2018015915A (es) Proteinas de enlace especifico y usos de las mismas.
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.